These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 21693430)

  • 1. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole.
    Ganguli R; Brar JS; Garbut R; Chang CC; Basu R
    Clin Schizophr Relat Psychoses; 2011 Jul; 5(2):75-9. PubMed ID: 21693430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
    Kim SH; Ivanova O; Abbasi FA; Lamendola CA; Reaven GM; Glick ID
    J Clin Psychopharmacol; 2007 Aug; 27(4):365-8. PubMed ID: 17632220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee JH; Lee YH; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2009; 32(5):243-9. PubMed ID: 19620849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
    Chen Y; Bobo WV; Watts K; Jayathilake K; Tang T; Meltzer HY
    J Psychopharmacol; 2012 Sep; 26(9):1201-10. PubMed ID: 22234928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case series: evaluation of the metabolic safety of aripiprazole.
    De Hert M; Hanssens L; van Winkel R; Wampers M; Van Eyck D; Scheen A; Peuskens J
    Schizophr Bull; 2007 May; 33(3):823-30. PubMed ID: 16940338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study.
    Takeuchi H; Uchida H; Suzuki T; Watanabe K; Kashima H
    Psychiatry Clin Neurosci; 2010 Feb; 64(1):104-6. PubMed ID: 19968829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial of aripiprazole in the treatment of first-episode schizophrenia.
    Lee HY; Ham BJ; Kang RH; Paik JW; Hahn SW; Lee MS; Lee MS
    Psychiatry Clin Neurosci; 2010 Feb; 64(1):38-43. PubMed ID: 20416024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
    Thomas P
    Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S115-22. PubMed ID: 17336766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
    Karunakaran K; Tungaraza TE; Harborne GC
    J Psychopharmacol; 2007 Jun; 21(4):453-6. PubMed ID: 17050662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.
    Takeuchi H; Suzuki T; Uchida H; Nakajima S; Nomura K; Kikuchi T; Manki H; Watanabe K; Kashima H
    J Clin Psychopharmacol; 2008 Oct; 28(5):540-3. PubMed ID: 18794650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review.
    Spurling RD; Lamberti JS; Olsen D; Tu X; Tang W
    J Clin Psychiatry; 2007 Mar; 68(3):406-9. PubMed ID: 17388710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
    McEvoy JP; Daniel DG; Carson WH; McQuade RD; Marcus RN
    J Psychiatr Res; 2007 Dec; 41(11):895-905. PubMed ID: 17631314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in values of cholesterol and tryglicerides after weight loss during treatment with aripiprazole in a patient with schizophrenia - Case report.
    Uzun S; Kozumplik O; Sedić B
    Psychiatr Danub; 2010 Jun; 22(2):373-6. PubMed ID: 20562787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Aripiprazole: a new atypical antipsychotic drug].
    Fischer B; Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Sep; 72(9):497-502. PubMed ID: 15365912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
    Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
    Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.